<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="814">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150561</url>
  </required_header>
  <id_info>
    <org_study_id>MuscleLab2020</org_study_id>
    <nct_id>NCT05150561</nct_id>
  </id_info>
  <brief_title>Muscle Dysfunction in Patients With Haematological Diseases</brief_title>
  <official_title>The Prevalence and the Prognostic Value of Sarcopenia Among Patients With Haematological Cancer Diseases - A Prospective Observational Cohort Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE: To evaluate the prevalence and prognostic value of sarcopenia in patients diagnosed&#xD;
      with hematological cancer diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some patients diagnosed with malignant hematological diseases are faced with poor prognosis&#xD;
      and thus must undergo a demanding course of treatment associated with severe deconditioning&#xD;
      potentially leading to worse prognostic outcomes. It is currently not well-described, to what&#xD;
      extend patients body composition at the point of diagnoses should be part of standard&#xD;
      clinical evaluation in order to optimize therapy-efficacy. Recent findings suggest that&#xD;
      pathophysiological alterations in skeletal muscle mass and function can have significant&#xD;
      implications for the risk of disease progression and long-term prognosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Whole body Lean body Mass</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization duration</measure>
    <time_frame>1 year post treatment</time_frame>
    <description>Total number days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>1 year post treatment</time_frame>
    <description>Risk of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year post treatment</time_frame>
    <description>Risk of mortality from any-cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appendicular lean mass</measure>
    <time_frame>Baseline and 6 after treatment start</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole body fat percentage</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral fat mass</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral content</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Dual-energy X-ray Absorptiometry (DXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking capacity</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Maximum 10 meter walking speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lower body physical function</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>30 seconds Sit-To-Stand test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum leg power</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Leg extensor power test (Nottingham Power Rig)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hand grip strength</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Maximum strength test by handgrip dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Blood values are registered from the patients hospital record in relation to assessments. C-reactive protein (CRP) and leucocytes are registered as they are inflammation markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatinine</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Blood values are registered from the patients hospital record in relation to assessments. Creatinine is registered due to their relation to muscle strength..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Blood values are registered from the patients hospital record in relation to assessments. Hemoglobin is registered due to their relation to muscle strength.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body fat percentage</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Bioelectrical Impedance Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fat mass</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Bioelectrical Impedance Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fat-free mass</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Bioelectrical Impedance Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle mass</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Bioelectrical Impedance Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone mass</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Bioelectrical Impedance Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total body water</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>Bioelectrical Impedance Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>European Organisation for Research and Treatment of Cancer Quality of LifeQuestionnaire, Version 3.0 Scores range from 0 to 100; a higher score represents a higher (&quot;better&quot;) level of functioning, or a higher (&quot;worse&quot;) level of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity level</measure>
    <time_frame>Baseline and 6 months after treatment start</time_frame>
    <description>The International Physical Activity Questionnaires, short form. The Questionnaires covers the frequency and duration of vigorous, moderate, and walking activities over the last 7 days, as well as a single-item question on weekday sitting. Using the instrument's scoring protocol, total weekly physical activity can be calculated to three levels of physical activity and the interpretation of the questionnaire can be categorized in low, moderate and high physical activity, based on the stated time and Metabolic Equivalent of Task (METs min/week) used in different types of activities.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort I - Patients newly diagnosed with malignant lymphoma (n=72)</arm_group_label>
    <description>These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II - Patients newly diagnosed with acute leukaemia (n=72)</arm_group_label>
    <description>These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort III - Patients newly diagnosed with multiple myeloma (n=72)</arm_group_label>
    <description>These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with malignant lymphomas, acute leukaemia and multiple myeloma referred&#xD;
        to treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Patients diagnosed with malignant lymphomas, acute leukaemia and multiple myeloma&#xD;
        referred to treatment at the Department of Haematology, Rigshospitalet.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age: &lt;18&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Physical or mental disabilities precluding test of muscle function&#xD;
&#xD;
          -  Inability to read and understand Danish.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Christensen, PhD</last_name>
    <phone>004535458511</phone>
    <email>jan.christensen.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Noerregaard Groenset, MSc</last_name>
    <phone>004535459581</phone>
    <email>charlotte.groenset@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Christensen, PhD</last_name>
      <phone>004535458511</phone>
      <email>jan.christensen02@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Noerregaard Groenset, MSc</last_name>
      <phone>004535459581</phone>
      <email>charlotte.groenset@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Charlotte Noerregaard Groenset, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Jan Christensen</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>Hematological cancer diseases</keyword>
  <keyword>Muscle mass</keyword>
  <keyword>Muscle strength</keyword>
  <keyword>Complications</keyword>
  <keyword>Patient reported outcomes</keyword>
  <keyword>Physical function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not provided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

